Ardelyx

Showing 3 posts of 3 posts found.

Ardelyx’s tenapanor combo meets all key goals at Phase 3 in hyperphosphatemia patients on dialysis

September 4, 2019
Research and Development Ardelyx, pharma, tenapanor

Ardelyx has revealed that its small molecule, non-binder, phosphate absorption inhibitor tenapanor met all primary and key secondary endpoints at …

Strong IBS and constipation Phase 3 data sends Ardelyx shares rocketing 60%

October 12, 2017
Research and Development Ardelyx, pharma, pharmaceuticals, tenapanor

Ardelyx has confirmed that its NHE3 inhibitor tenapanor met all its primary and secondary endpoints in the study of its …

AZ licences renal disease compound

October 9, 2012
Research and Development, Sales and Marketing Ardelyx, AstraZeneca, NHE3

AstraZeneca has signed an agreement giving it worldwide exclusive rights to California-based Ardelyx’s NHE3 inhibitor programme targeting liver and kidney …

The Gateway to Local Adoption Series

Latest content